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Abstract
Background:  A major determinant of retrovirus host range is the presence or absence of
appropriate cell-surface receptors required for virus entry. Often orthologs of functional receptors
are present in a wide range of species, but amino acid differences can render these receptors non-
functional. In some cases amino acid differences result in additional N-linked glycosylation that
blocks virus infection. The latter block to retrovirus infection can be overcome by treatment of
cells with compounds such as tunicamycin, which prevent the addition of N-linked oligosaccharides.
Results:  We have discovered that treatment of cells with liposomes composed of
phosphatidylserine (PS) can also overcome the block to infection mediated by N-linked
glycosylation. Importantly, this effect occurs without apparent change in the glycosylation state of
the receptors for these viruses. This effect occurs with delayed kinetics compared to previous
results showing enhancement of virus infection by PS treatment of cells expressing functional virus
receptors.
Conclusion:  We have demonstrated that PS treatment can relieve the block to retrovirus
infection of cells expressing retroviral receptors that have been rendered non-functional by
glycosylation. These findings have important implications for the current model describing
inhibition of virus entry by receptor glycosylation.
Background
Many of the cellular receptors for retroviruses have been
well characterized (for review see [1]). These receptors
perform a wide variety of cellular functions and can be
single-transmembrane, GPI-anchored, or multiple-mem-
brane-spanning proteins. The presence or absence of func-
tional receptors on the cell surface is a major determinant
of virus tropism. In some cases, otherwise functional
receptors are glycosylated and therefore unusable by par-
ticular retroviruses [2-6]. Since these sites of glycosylation
are often near the binding sites used by viruses, glycosyla-
tion is thought to be an important defense mechanism
evolved by cells in their battle against virus infection (for
example see [7]).
One particularly well-studied example of glycosylation-
blocked receptors involves those for the cat endogenous
retrovirus RD114, which is unable to enter NIH 3T3
mouse cells unless these cells have been treated with
agents, including tunicamycin, that prevent the addition
of N-linked oligosaccharides to proteins in the endoplas-
mic reticulum. The receptor for RD114 in tunicamycin-
Published: 09 August 2005
Retrovirology 2005, 2:49 doi:10.1186/1742-4690-2-49
Received: 19 May 2005
Accepted: 09 August 2005
This article is available from: http://www.retrovirology.com/content/2/1/49
© 2005 Coil and Miller; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Retrovirology 2005, 2:49 http://www.retrovirology.com/content/2/1/49
Page 2 of 7
(page number not for citation purposes)
treated NIH 3T3 cells is a multiple-membrane spanning
protein called ASCT1 (standard name SLC1A4), which is
a neutral amino acid transporter [5]. RD114 also uses a
closely related human protein, ASCT2 (standard name
SLC1A5, also called RDR) as a receptor [8,9]. Sequence
differences in the mouse ortholog of human ASCT2 pre-
vent it from serving as a receptor, even after tunicamycin
treatment [5].
Other examples of glycosylation-blocked receptors are the
hamster and rat orthologs of the receptor for Moloney
murine leukemia virus (MoMLV), CAT1 (standard name
SLC7A1). Prevention of receptor glycosylation by treat-
ment of rat or hamster cells with tunicamycin relieves the
block to infection by MoMLV [3,10]. Like ASCT1 and
ASCT2, CAT1 is an amino acid transporter, in this case for
lysine, arginine, and ornithine [11-13]. If the N-linked
glycosylation sites of mouse ASCT1, hamster CAT1, or rat
CAT1 are removed through mutagenesis, these proteins
are fully functional as virus receptors [3,10,14]. To date,
removal of N-linked glycosylation through either muta-
genesis of the oligosaccharide attachment sites or by treat-
ment with inhibitors of glycosylation are the only ways
known to relive the block to infection by RD114 and
MoMLV viruses in the respective rodent cell lines.
We recently have shown that treatment of target cells with
phosphatidylserine (PS) enhances enveloped virus infec-
tion by up to 20-fold [15]. This effect is not observed with
other phospholipids, and is thought to occur through an
enhancement of virus fusion [15]. Importantly, in all
cases tested where a functional receptor was present, PS
treatment enhanced virus infection. Conversely, when a
functional receptor was not present, PS treatment did not
allow infection of target cells. Here we show that phos-
phatidylserine treatment can relieve the block to infection
mediated by glycosylation-blocked receptors and further
investigate this phenomenon.
Results
PS treatment allows infection of cell types expressing 
glycosylation-blocked receptors
Our previous work demonstrated that PS-dependent
enhancement of infection requires functional receptors
[15], and we will refer to this effect as "non-specific
enhancement" of virus infection by PS. We wanted to
extend these observations by examining the effects of PS
on virus entry in the case where the receptor was present
but was inactive due to receptor glycosylation. We used
the LAPSN retroviral vector [16] that encodes human pla-
cental alkaline phosphatase (AP) as a marker for infec-
tion. Viruses carrying this vector contained Gag-Pol
proteins from MoMLV and Env proteins from either
MoMLV or RD114. For simplicity we will call these viruses
MoMLV or RD114 vectors, respectively. MoMLV vectors
are unable to enter CHO cells and RD114 vectors are una-
ble to enter NIH 3T3 cells unless these cells are first treated
with tunicamycin to prevent receptor glycosylation [3-5].
Table 1 shows that pretreatment of CHO and NIH 3T3
cells with 400 µM PS for 24 h allowed efficient entry of
MoMLV and RD114 vectors, respectively. Hereafter we
will refer to this effect as "glycosylation-specific enhance-
ment" by PS, in contrast to the "non-specific enhance-
ment" described in our previous work.
PS treatment does not affect receptor glycosylation
A simple explanation for these results might be that PS
inhibits receptor glycosylation, as does tunicamycin treat-
ment. As described above, murine ASCT1 functions as a
receptor for RD114 in NIH 3T3 cells treated with tuni-
camycin [5]. Treatment of cell lysates with peptide N-gly-
cosidase F (PNGase F) causes an increase in the
electrophoretic mobility of ASCT1 as a result of removal
of the N-linked glycosylation [14]. We attempted to exam-
ine the glycosylation status of a myc-tagged ASCT1 pro-
tein in NIH 3T3 cells but were unable to clearly visualize
the protein due to technical problems including high
background antibody binding. However, we were able to
examine the glycosylation state of a hemagglutinin (HA)-
tagged human ASCT2 protein in NIH 3T3/ASCT2 cells
(Figure 1A). In the non-PS treated cells there was a clear
Table 1: PS treatment allows infection of cells expressing glycosylation-blocked retrovirus receptorsa
Target cells Vector PS treatment Vector titer (AP+ FFU/ml)
NIH 3T3 RD114 - <1
RD114 + 2.3 × 104
CHO-K1 MoMLV - <5
MoMLV + 2.3 × 103
a Virus infections and PS preparation were performed as described in Materials and Methods. Where indicated, cells were treated with 400 µM PS 
for 24 h. Data shown are the averages of three independent experiments, each done in duplicate. Values from different experiments varied no more 
than three-fold.Retrovirology 2005, 2:49 http://www.retrovirology.com/content/2/1/49
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increase in mobility of ASCT2 when incubated with
PNGase F, demonstrating that this protein is normally gly-
cosylated. Furthermore, none of the protein is found in
the unglycosylated state prior to PNGase F treatment. The
same mobility shifts were observed in cells treated with
PS, indicating that treatment with PS does not affect the
glycosylation state of this protein in NIH 3T3 cells.
To examine ASCT1 glycosylation directly, we transiently
expressed a myc-tagged mouse ASCT1 in 293T cells and
examined the effects of PS treatment on glycosylation
(Figure 1B). These cells were treated with either 35 µM PS
or were left untreated. This concentration of PS was cho-
sen because it induced the highest vector infection rate in
293T cells and a high concentration of PS (400 µM) was
toxic to 293T cells (data not shown). As for the HA-tagged
ASCT2 protein, there was no detectable unglycosylated
receptor present in the PS treated cells, indicating that
ASCT1 glycosylation is unaffected by PS treatment.
The non-specific enhancement of infection by PS 
treatment occurs rapidly
We have previously postulated that the non-specific
enhancement of virus infection by PS occurs through an
effect on virus fusion [15]. If this were true, the effect
should happen relatively quickly since all that is required
is for the PS liposomes to fuse with the plasma membrane
of the cell and change the physical characteristics of the
membrane. We undertook infections using RD114 vector
on normally infectable NIH 3T3/ASCT2 cells given only a
short exposure to PS, in contrast to the 24 h treatment
used in previous experiments. Cells were treated with PS
for 1 h, virus was added for 2 h, and the cells were
trypsinized and replated. With only 1 h of PS treatment,
virus infection was increased almost 4-fold. This experi-
ment was repeated twice with the same results. While not
as much as the full 10 to 20-fold increase in infection
when treated for 24 h, this demonstrates that the effect of
PS on virus infection is indeed rapid. However when the
parental NIH 3T3 cells, containing the glycosylation-
blocked receptor, were treated in the same manner, no
infection by the RD114 vector was observed (data not
shown).
The non-specific and glycosylation-specific enhancements 
of infection have different time courses
The preceding results suggest that the glycosylation-spe-
cific enhancement of PS treatment is delayed when com-
pared to the non-specific enhancement of virus infection.
To compare these two effects we examined RD114 vector
infection of both NIH 3T3 cells and NIH 3T3/ASCT2 cells
over a longer time course. Cells were treated with PS at
time points from 4–24 h and were then infected with the
RD114 vector. The cell surface PS levels were also meas-
ured at each timepoint by annexin-V staining. We found a
linear relationship between the time after PS addition and
the amount of PS present in the outer leaflet of the mem-
brane (Figure 2, top panel). Furthermore, there was a
direct relationship between the amount of PS present in
the membrane and infection of normally-infectable NIH
3T3/ASCT2 cells by the RD114 vector (Figure 2, middle
panel). In contrast, there was a long delay in the increase
in RD114 vector infection of NIH 3T3 cells following PS
addition, with the major enhancement of virus infection
occurring after 12 h Figure 2, bottom panel).
Effects of PS at reduced concentrations on RD114 vector 
infection of NIH 3T3 cells
The long delay between addition of PS and the glycosyla-
tion-specific enhancement of virus infection suggests that
Analysis of N-linked oligosaccharide modification of ASCT1  and ASCT2 with or without PS treatment Figure 1
Analysis of N-linked oligosaccharide modification of 
ASCT1 and ASCT2 with or without PS treatment. 
(A) NIH 3T3/ASCT2 cells that express HA-tagged human 
ASCT2 were treated with 400 µM PS for 24 h. Cell lysates 
were treated with or without PNGase F as described in 
Materials in Methods, and lysates were analyzed by Western 
immunoblotting with anti HA-tag monoclonal antibody. (B) 
293T cells were transiently transfected with a myc-tagged 
murine ASCT1 expression plasmid. 400 µM PS was added 24 
h post-transfection. Cell lysates were made 48 h post-trans-
fection, were treated with or without PNGase F as described 
in Materials in Methods, and were analyzed by Western 
immunoblotting with anti Myc-tag monoclonal antibody.
A
PNGase F
PS
−
−+
− ++
+ −
glycosylated
unglycosylated
ASCT2
PS
B
PNGase F −
−+
− ++
+ −
glycosylated
unglycosylated
ASCT1
82
64
48
115
82
64
48
kDa
kDaRetrovirology 2005, 2:49 http://www.retrovirology.com/content/2/1/49
Page 4 of 7
(page number not for citation purposes)
a threshold amount of PS in the cell membrane may be
required for the observed enhancement. To address this
possibility we undertook a 24-h time course as described
above, using half the amount of PS (200 µM) (Figure 3).
The total amount of PS incorporated into the plasma
membrane was reduced at each timepoint, and saturation
did not appear to be reached. The reduced incorporation
of PS had the result of increasing the delay of RD114 vec-
tor infection of NIH 3T3 cells from 12 to more than 16 h,
supporting the hypothesis that a threshold amount of PS
is required for the glycosylation-specific enhancement of
virus infection.
The dose-response of non-specific and glycosylation-
specific enhancement of virus infection by PS differs
It appears from the results shown in Figure 3 that there is
a simple relationship between amount of PS present in
the membrane and the non-specific enhancement of virus
infection. We next examined the effect of 24 h treatment
with various concentrations of PS on RD114 vector infec-
tion of both NIH 3T3/ASCT2 cells and NIH 3T3 cells (Fig-
ure 4). Infection and annexin-V measurements were
undertaken as previously described. At very low levels of
Time course of cell-surface PS levels and cell susceptibility to  RD114 vector infection of NIH 3T3/ASCT2 and NIH 3T3  cells during treatment with PS Figure 2
Time course of cell-surface PS levels and cell suscep-
tibility to RD114 vector infection of NIH 3T3/ASCT2 
and NIH 3T3 cells during treatment with PS. Cells 
were plated on day 0. 400 µM PS was added on day 1 at 24, 
20, 16, 12, 8, and 4 h pre-infection. At the time of infection, 
cells were either infected with the RD114 vector 
[LAPSN(RD114)] or were assayed for cell-surface PS levels 
by using annexin-V. Top panel: annexin-V staining of NIH 3T3 
cells was undertaken as described in Materials and Methods. 
Middle panel: LAPSN(RD114) infection of NIH 3T3/ASCT2 
cells. Bottom Panel: LAPSN(RD114) infection of NIH 3T3 
cells. Data points shown are means of duplicates, and each 
series represents an independent experiment. Data is repre-
sented as a percentage of the highest value observed.
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Effects of PS at a reduced concentration on RD114 vector  infection of NIH 3T3 cells Figure 3
Effects of PS at a reduced concentration on RD114 
vector infection of NIH 3T3 cells. PS liposomes were 
generated and added to NIH 3T3 cells at either 400 µM or 
200 µM concentration. Cells were analyzed for cell-surface 
PS levels by using annexin-V or were infected with the 
RD114 vector [LAPSN(RD114)] as described in Materials 
and Methods. Top panel: Annexin-V staining of NIH 3T3 
cells. Bottom panel: LAPSN(RD114) infection of NIH 3T3 
cells. Data shown are the average of duplicates. The entire 
experiment was repeated with very similar results.
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PS, which are not detectable by annexin-V, no infection
on either cell type was observed. As soon as an increase in
PS levels was observed, there was a corresponding increase
in RD114 infection of the NIH 3T3/ASCT2 cells. However,
infection of NIH 3T3 cells was not detectable until a
higher concentration of PS was reached, further support-
ing the hypothesis of a required threshold concentration
for infection through the glycosylation-specific pathway.
Discussion
Here we report that PS treatment of target cells containing
glycosylation-blocked viral receptors allows virus infec-
tion. Importantly, this occurs without removal of the oli-
gosaccharide itself, unlike the case with tunicamycin
treatment. Furthermore, this glycosylation-specific effect
takes place in NIH 3T3 cells on a different timescale than
the non-specific enhancement of virus infection by PS,
and appears to require a threshold concentration of cell-
surface PS. When NIH 3T3 cells are treated with 200 µM
PS, they reach the same level of infectivity after 24 h as
when treated with 400 µM PS, but take longer before
infection is observable, suggesting that the observed
enhancement of infection is not merely a signaling cas-
cade initiated by the addition of PS to the cell. One expla-
nation for such a long delay is that de novo protein
synthesis is required for the glycosylation-specific effect of
PS treatment. Additional experiments will be needed to
address this question. Unfortunately, preliminary experi-
ments have demonstrated that PS treatment combined
with inhibition of protein synthesis by cycloheximide is
lethal to cells (data not shown), further complicating this
analysis.
Additionally we have shown that the non-specific
enhancement by PS occurs rapidly, and there is a direct
correlation between amount of cell-surface PS and the
amount of non-specific enhancement of virus infection.
This result supports our previous hypothesis that the non-
specific enhancement occurs through an influence of virus
fusion.
Our results suggest that the block to infection of glyco-
sylated receptors may occur at a different stage of virus
entry than previously assumed. It has been proposed that
glycosylation prevents MoMLV or RD114 from binding to
their cognate receptors, thereby terminating virus entry at
a very early step [7]. However, our results demonstrate
that these two viruses can still infect cells containing fully
glycosylated receptors. However, we have not ruled out
the possibility that PS might induce subtle changes in
receptor glycosylation, such as alterations in the structure
or branching of the N-linked oligosaccharides, that might
affect virus entry.
Instead of a block to virus binding, it is possible that PS
affects the packing or mobility of the receptors in the
plasma membrane. Several groups have suggested that
receptor clusters, or multivalent Env-receptor complexes
are required for retrovirus infection [17-21]. For example,
an ASLV-A virion appears to require multiple contacts
with receptors in order to enter a fusogenic state [21]. It is
Effects of PS concentration on cell-surface PS levels and  RD114 vector infection of NIH 3T3 or NIH 3T3/ASCT2 cells Figure 4
Effects of PS concentration on cell-surface PS levels 
and RD114 vector infection of NIH 3T3 or NIH 3T3/
ASCT2 cells. PS liposomes were generated and added to 
cells at concentrations of 0, 6.4, 32, 80, 240, 320, and 400 
µM. Annexin-V staining and infections were undertaken as 
described in Materials and Methods. Top panel: Annexin-V 
staining of NIH 3T3 cells. Middle panel: RD114 vector 
[LAPSN(RD114)] infection of NIH 3T3/ASCT2 cells. Bottom 
panel: LAPSN(RD114) infection of NIH 3T3 cells. Data 
shown are the average of duplicates. The entire experiment 
was repeated twice with very similar results.
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possible that glycosylated receptors are normally unable
to pack as tightly, or move through the membrane as rap-
idly as their unglycosylated forms in order to facilitate
virus infection. In this model, the disruption to the
plasma membrane caused by PS treatment could allow
sufficient concentrations of receptor to contact the viral
Env proteins and initiate fusion. Exogenous PS has been
shown to affect the curvature and stability of a lipid
bilayer, providing a mechanism for this disruption
[22,23]. On the other hand, fewer receptor contacts could
be required by the virus to form a fusion pore if the acti-
vation energy for fusion to occur has been lowered by PS
treatment [15]. Similarly, it is possible that the glycosyla-
tion of the receptors prevents the membranes from com-
ing in close enough contact to fuse, but that the
destabilization of the plasma membrane by PS increases
the distance at which this fusion can occur. Further study
will be required to understand the mechanism of glyco-
sylation-specific enhancement of virus entry through PS
treatment.
Conclusion
In summary, these results expand on our previous find-
ings regarding the mechanism of enhancement of virus
infection by PS treatment, and demonstrate an effect of PS
treatment on cells containing glycosylation-blocked
receptors. The ability to promote CHO-K1 and NIH 3T3
infection by MoMLV and RD114 vectors without tuni-
camycin treatment should be of interest to researchers
studying these viruses and to those studying the nature of
the glycosylation-induced block to retrovirus infection.
Methods
Cell culture and plasmids
NIH 3T3 thymidine kinase-deficient mouse embryo
fibroblasts [24], and 293T human embryonic kidney cells
[25] were maintained at 37°C and 5% CO2 in Dulbecco's
modified Eagle medium with a high concentration of glu-
cose (4.5 g per liter) and 10% FBS. CHO-K1 hamster cells
(ATCC CCL-61) were maintained in Minimal Essential
Medium Alpha at 37°C and 5% CO2. Clonal NIH 3T3
cells expressing an HA-tagged human ASCT2 (NIH 3T3/
ASCT2 cells) were generated by transduction with the
retroviral vector LNCRDRHA, that contains a human RDR
(ASCT2) cDNA with a carboxy-terminal HA tag cloned
into the LNCX retroviral vector [26]. The expression plas-
mid containing the myc-tagged murine ASCT1 was kindly
provided by David Kabat [14].
Virus production
LAPSN is a Moloney murine leukemia virus (MoMLV)-
based vector that encodes human placental alkaline phos-
phatase (AP) and neomycin phosphotransferase [16].
LAPSN containing viruses were generated from the fol-
lowing packaging lines expressing the indicated Env pro-
teins; FlyRD (RD114) [27], and PE501 (MoMLV) [26]. All
retroviral vectors used in these studies were harvested in
medium exposed to producer cells and were centrifuged at
1,000 × g for 5 min to remove cells and debris.
Virus assays
All retrovirus vector infections were undertaken as fol-
lows. On day 0, cells were plated at 5 × 104 cells/well in 6-
well dishes. On day 1, fresh phospholipid liposomes were
generated and added to cells at 400 µM (unless otherwise
noted). On day 2, the medium was replaced with fresh
medium containing 4 µg/ml Polybrene and virus was
added to the wells. On day 5 the cells were fixed with
0.5% glutaraldehyde and stained for AP expression. For
the 24-h infection time courses, a large batch of PS lipo-
somes was produced on day 1, and was added to cells
every 4 h from 0–24 h. At 24 h, cells were either infected
as described above or were prepared for annexin-V
labeling.
Annexin-V labeling
Alexa Fluor 488-conjugated annexin-V, propidium iodide
(PI), and annexin binding buffer were obtained from the
Vybrant Apoptosis Assay Kit #2 (Molecular Probes,
Eugene, OR). Annexin-V labeling was performed using a
slight variation of the manufacturer's protocol as previ-
ously described [28]. The geometric mean fluorescence of
10,000 cells was obtained for the unlabeled and labeled
cell populations, and the mean of the unlabeled cells was
subtracted from the mean of the labeled cells to determine
the relative amount of cell-surface PS for each sample.
Dead cells were excluded from analysis on the basis of PI
staining.
Generation of liposomes
L-α-phosphatidyl-L-serine was obtained as a 10 mg/ml
solution in chloroform:methanol (95:5) (Sigma, St Louis,
MO). To generate liposomes, phospholipid was dried in a
glass tube under nitrogen, and resuspended in PBS to a
final concentration of 5 mM. This solution was sonicated
on ice 3 times for 5 min each, using a W-385 sonicator
with a microtip on output level 3 (Heat Systems
Ultrasonics). The liposomes were filtered through a 0.2
µm pore-size syringe filter and were used immediately
unless otherwise described.
Western blot analysis
For analysis of the HA-tagged human ASCT2, washed cells
were lysed for 30 min at 4°C in lysis buffer (50 mM Tris-
HCL [pH 8.0], 150 mM NaCl, and 1% NP-40), and centri-
fuged at 970 × g for 10 min to remove nuclei and cell
debris. The supernatant was boiled for 10 min after addi-
tion of SDS and β-mercaptoethanol to final concentra-
tions of 0.5% and 1%, respectively. The sample was
divided, an equal amount of either PNGase F (NewRetrovirology 2005, 2:49 http://www.retrovirology.com/content/2/1/49
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England Biolabs) or lysis buffer was added to each half,
and the samples were kept at 37°C for 3 h. The treated and
untreated samples were analyzed by electrophoresis in a
10% polyacrylamide gel containing 0.1% SDS. The pro-
teins were transferred to nitrocellulose membranes,
blocked in 5% powdered milk, incubated with appropri-
ate concentrations of anti-HA primary and secondary anti-
bodies, and visualized using a chemiluminescence kit
(Amersham Biosciences). Analysis of ASCT1 was per-
formed following transient transfection of 293T cells with
a myc-tagged expression vector for murine ASCT1 [14]
using the calcium phosphate method [29]. Cell lysates
were collected at 48 h post-transfection and were treated
as described above, followed by incubation of Western
blots with appropriate concentrations of anti-Myc tag pri-
mary and secondary antibodies.
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